Energy Fuels' U.S. Rare Earth Processing Expansion Boasts Lower-Than-Expected CAPEX, Significant Annual EBITDA, and Among the Lowest Cost NdPr Production in the World

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) (Energy Fuels or the Company), a leading U.S. producer of uranium, rare earth elements (REEs), and other critical materials, today released the results of a ...

Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica

The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is ...
Medical Dialogues

Tenecteplase Noninferior to Alteplase for Mechanical Prosthetic Heart Valve Thrombosis: TENET Trial Suggests

Thrombolytic therapy with alteplase is widely used for symptomatic PVT, but evidence comparing it directly with tenecteplase ...
Medical Dialogues

Full MIST2 Intrapleural Enzyme Therapy Linked to Better Outcomes in Pleural Infection Cases: Study

A new study published in the Chest Journal showed that Full MIST2 dosing of intrapleural enzyme therapy (IET) was Linked to ...
Daily Voice on MSN

NY warns consumers after med spa crackdown finds injuries

New York officials are warning consumers to use extreme caution when seeking med spa services after a statewide investigation ...
News-Medical.Net on MSN

UVA researcher wins $700,000 for promising ovarian cancer research

Promising ovarian cancer research by Melanie Rutkowski, PhD, at the University of Virginia Comprehensive Cancer Center has ...
Pulmonology Advisor

IET Protects Patients With Complicated Parapneumonic Pleural Effusion or Empyema

Intrapleural enzyme therapy (IET) improves outcomes in adult inpatients with complicated parapneumonic pleural effusion or empyema.
BioSpace

Resolve Therapeutics to Present at International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS)

MIAMI, Nov. 17, 2025 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical biopharmaceutical company pioneering non-immunosuppressive drugs for inflammatory diseases today announced it will ...
The New York Times

Are A.I. Therapy Chatbots Safe to Use?

Psychologists and technologists see them as the future of therapy. The Food and Drug Administration is exploring whether to regulate them as medical devices. Psychologists and technologists see them ...
ahajournals.org

Onset to Treatment Time and Early Neurological Deterioration of Dual Antiplatelet Therapy Versus Alteplase in Minor Stroke

The ARAMIS (Antiplatelet Versus R‐tPA [Recombinant Tissue Plasminogen Activator] for Acute Minor Ischemic Stroke) trial established that dual antiplatelet therapy (DAPT) is noninferior to intravenous ...